There’s a lot to be optimistic about in the Technology sector as 3 analysts just weighed in on HubSpot (HUBS – Research Report), Triumph Group (TGI – Research Report) and SPS Commerce (SPSC – Research Report) with bullish sentiments.
Wells Fargo analyst Michael Turrin maintained a Buy rating on HubSpot on February 6 and set a price target of $725.00. The company’s shares closed last Friday at $544.92.
According to TipRanks.com, Turrin has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
HubSpot has an analyst consensus of Strong Buy, with a price target consensus of $738.84, which is a 25.9% upside from current levels. In a report issued on February 11, BMO Capital also maintained a Buy rating on the stock with a $675.00 price target.
Triumph Group (TGI)
Robert W. Baird analyst Peter Arment reiterated a Buy rating on Triumph Group on February 10 and set a price target of $28.00. The company’s shares closed last Friday at $21.05.
According to TipRanks.com, Arment is a 5-star analyst with an average return of
Currently, the analyst consensus on Triumph Group is a Hold with an average price target of $22.50.
SPS Commerce (SPSC)
Robert W. Baird analyst Joseph Vruwink maintained a Buy rating on SPS Commerce on February 10 and set a price target of $156.00. The company’s shares closed last Friday at $126.00.
According to TipRanks.com, Vruwink is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for SPS Commerce with a $173.20 average price target, representing a 36.5% upside. In a report issued on February 10, JMP Securities also maintained a Buy rating on the stock with a $160.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HUBS:
- What Do Wix Website Visits Tell Us About its Q4 Earnings Picture?
- Alibaba: Could its Fortunes Change in Q3?
- Eli Lilly’s Bebtelovimab Bags FDA Emergency Use Approval
- Stock Futures: Mixed Signals as Market Grapples with Inflation, Geo-Political Tensions
- Genpact Q4 Results Top Estimates; Issues Guidance